BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of three primary clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; BL-7010, a novel co-polymer for the treatment of celiac disease and gluten sensitivity; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The company's other therapeutic candidates comprise BL-8020, an orally available treatment for the hepatitis C virus, and other viral indications; and BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction. It also has a preclinical stage therapeutic candidate, BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas. The company has strategic collaboration with Novartis Pharma AG; and a collaboration with Merck. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.
http://www.priceseries.com/trade/BLRX-BioLineRx-Ltd-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2017072620170816.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments